CAL
MRNA icon

Capital Analysts LLC’s Moderna MRNA Stock Holding History

Capital Analysts LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
163
-9,016
-98% -$466K ﹤0.01% 1275
2026
Q1 		$466K Buy
9,179
+16
+0.2% +$746 0.01% 466
2025
Q4 		$270K Sell
9,163
-15
-0.2% -$408 0.01% 562
2025
Q3 		$237K Buy
9,178
+8,979
+4,512% +$250K 0.01% 565
2025
Q2 		$5K Hold
199
– – ﹤0.01% 1253
2025
Q1 		$6K Hold
199
– – ﹤0.01% 1199
2024
Q4 		$8K Buy
199
+21
+12% +$1K ﹤0.01% 1103
2024
Q3 		$12K Hold
178
– – ﹤0.01% 1002
2024
Q2 		$21K Buy
178
+152
+585% +$19.2K ﹤0.01% 851
2024
Q1 		$3K Hold
26
– – ﹤0.01% 1028
2023
Q4 		$3K Hold
26
– – ﹤0.01% 996
2023
Q3 		$3K Buy
26
+15
+136% +$1.67K ﹤0.01% 1029
2023
Q2 		$1K Sell
11
-10
-48% -$1.33K ﹤0.01% 978
2023
Q1 		$3K Buy
+21
New +$3.46K ﹤0.01% 905
2021
Q4 		– Sell
-100
Closed -$38K – 1019
2021
Q3 		$38K Buy
+100
New +$36.9K ﹤0.01% 617
2021
Q2 		– Sell
-200
Closed -$26K – 1042
2021
Q1 		$26K Buy
+200
New +$29K ﹤0.01% 679

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Capital Analysts LLC's MRNA Position: Q2 2026 in Review

Capital Analysts LLC reduced its Moderna (MRNA) stake by 98% in Q2 2026, selling an estimated $466K and leaving 163 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Capital Analysts LLC first reported a position in MRNA in Q1 2021 and has held it in 16 quarters since. The position peaked at $466K in Q1 2026. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Capital Analysts LLC held 163 shares of Moderna worth $11K as of Q2 2026.
  • Capital Analysts LLC sold 9,016 Moderna shares in Q2 2026, an estimated $466K.
  • Moderna made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1275 holding.
  • Capital Analysts LLC first reported a position in Moderna in Q1 2021 and has held it in 16 quarters since.
  • Capital Analysts LLC's Moderna position peaked at $466K in Q1 2026.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.